How to Place a Medical Device on the Great Britain Market in 2026: When a Valid CE Mark Is Enough, When UKCA Is Required, Appointing a UK Responsible Person, MHRA Registration, and the June 2025 PMS Rules That Already Apply

What Is in Force on the Great Britain Market Today: CE Recognition, UKCA, or Both?

For an international medical device distributor evaluating a new product line or an overseas manufacturer planning an entry into the United Kingdom, commercial discussions around post-Brexit compliance remain clouded by outdated consultancy advice. Many buyers and commercial teams continue to operate under the misconception that the UKCA (UK Conformity Assessed) mark became mandatory immediately following the UK's departure from the European Union, or that selling a CE-marked device in England, Scotland, or Wales is currently unlawful without a dual UKCA audit. That assumption is legally incorrect ¹.

As of 23 August 2026, the regulatory framework governing the Great Britain (GB) market—comprising England, Wales, and Scotland—is a dual-track system operating under the Medical Devices Regulations 2002 (SI 2002 No. 618, as amended, known as the UK MDR 2002) and The Medical Devices (Amendment) (Great Britain) Regulations 2023 (SI 2023 No. 627) ¹⁰. Under this statutory framework, a medical device can be lawfully placed on the Great Britain market through either of two distinct conformity routes:

• The CE-Mark Recognition Route: Devices that hold a valid CE mark issued under European Union directives or regulations can continue to be placed on the GB market under legislated transitional periods lasting until 30 June 2028 or 30 June 2030, depending on the underlying certification.
• The UKCA Marking Route: Manufacturers can apply a UKCA mark based on a conformity assessment conducted by a UK Approved Body (or through self-declaration for eligible low-risk Class I devices) under the provisions of the UK MDR 2002.

According to official statistics published by the Medicines and Healthcare products Regulatory Agency (MHRA) during its policy announcements, approximately 90% of all medical devices currently used in the Great Britain healthcare system rely on CE marking rather than standalone UKCA certification ⁹. For the vast majority of international manufacturers—including Chinese and Asian producers of sterile single-use surgical consumables, catheter securement devices, endovenous laser fibers, and perioperative dressings—maintaining a compliant EU CE certificate remains the primary and most cost-effective gateway to the British market.

However, relying on CE recognition does not mean that an overseas manufacturer can simply ship boxes into a British warehouse. While the product's design dossier, clinical evaluation, and conformity certificate can leverage European harmonisation, the market placement process within Great Britain is governed entirely by UK domestic law ¹. Every non-UK manufacturer must satisfy four mandatory domestic gates before the first commercial unit crosses the border: appointing a legally designated UK Responsible Person (UKRP), completing formal device registration on the MHRA's Device Online Registration System (DORS), notifying all British importers, and executing post-market surveillance in full accordance with Great Britain's June 2025 statutory overhaul ⁷.

Which CE Certificates Still Get a Device onto the GB Market, and Until Which Date (2028 vs 2030)?

The legal mechanism enabling CE-marked devices to enter Great Britain is codified in Statutory Instrument 2023 No. 627 ¹⁰, which amended the UK MDR 2002 to prevent acute supply disruptions in the National Health Service (NHS) and the private medical sector. The transitional recognition timelines are strictly stratified based on the underlying European legislation under which the device was certified and whether the certificate remains legally valid under EU extension rules ⁵.

To determine the exact statutory cut-off date for placing a CE-marked device on the GB market, distributors and regulatory managers must apply the statutory acceptance rules outlined below:

A critical nuance that trips up international supply contracts is the distinction between 'certificate expiry' and the statutory ceiling. For a device certified under the legacy Medical Devices Directive (MDD), the GB cut-off is the sooner of certificate expiry or 30 June 2028 ⁵. If an MDD certificate expired in November 2024 and the manufacturer did not formally satisfy the conditions of EU Regulation 2023/607 (such as lodging a formal MDR application with an EU Notified Body and signing a written agreement before the prescribed deadlines), that certificate is invalid in Europe—and by direct legal consequence, it cannot be used to place devices on the GB market ¹.

Distributors qualifying overseas suppliers must therefore verify the validity of the underlying CE certificate through independent notified body registers before relying on CE recognition. For a step-by-step methodology on validating certificate authenticity, scope, and MDD extension validity via NANDO and EUDAMED, distributors should consult our dedicated guide on verifying CE certificates and notified-body designations.

What Is UKCA Actually Assessed Against, and When Would a Buyer Insist on It Anyway?

When an overseas manufacturer or private-label buyer chooses or is required to pursue the UKCA mark, a common misunderstanding is that UKCA represents a 'British version of the EU MDR'. In reality, the legal basis of UKCA marking in 2026 remains rooted in historical directive-era standards ².

Under the UK MDR 2002 (specifically Parts II, III, and IV, as modified by Schedule 2A), the technical requirements, essential requirements, and conformity assessment annexes for UKCA marking mirror the old EU Directives: MDD 93/42/EEC for general medical devices, AIMDD 90/385/EEC for active implants, and IVDD 98/79/EC for in vitro diagnostics ². A UK Approved Body assessing a sterile single-use circumcision device or an endovenous laser fiber for UKCA marking audits the technical file against the UK MDR 2002 Essential Requirements—not against the 23 General Safety and Performance Requirements (GSPRs) of EU MDR Annex I.

Given that UKCA requires a standalone commercial contract with a UK Approved Body, separate audit fees, and ongoing UK surveillance, why would a manufacturer or British distributor choose to pursue UKCA marking today instead of riding CE recognition? There are four specific commercial and operational scenarios where UKCA is necessary or advantageous:

1. No Existing EU CE Certificate: If a manufacturer holds only domestic Chinese NMPA registration, US FDA 510(k) clearance, or ISO 13485 certification, the CE-recognition pathway is completely unavailable. Sourcing the device for Great Britain requires either obtaining an EU MDR certificate or undergoing UKCA conformity assessment.
2. Expired or Ineligible MDD Certificates: If a legacy MDD certificate expired without meeting the EU MDR Article 120 extension conditions, or if the device is a remaining Class I / general IVD self-declared product that still would not need a notified body under MDR/IVDR, CE recognition cannot be used for new GB placements.
3. Long-Term Supply Chain De-Risking: Certain NHS hospital trusts, procurement consortia, and institutional tenders award preference points or require suppliers to demonstrate a concrete UKCA transition roadmap to guarantee uninterrupted supply beyond the 2028/2030 deadlines.
4. UK-Specific Customisation or Indications: If a device is modified specifically for the British clinical market (e.g., custom procedure kit assemblies or dedicated surgical configurations) in a manner not covered by the manufacturer's EU CE scope, a domestic UKCA file allows immediate commercialisation without amending the European dossier.

Who Must Be the UK Responsible Person, and Can a Distributor or Importer Wear That Hat?

Whenever a medical device manufacturer is located outside the United Kingdom—whether in China, the United States, or the European Union—the UK MDR 2002, as amended, requires designation of a single UK Responsible Person (UKRP) before any device is placed on the Great Britain market ¹. The UKRP acts as the primary legal and regulatory representative of the manufacturer before the MHRA. (Regulation 7A is the duty to keep MHRA registration details current; it is not the UKRP appointment rule.)

The UKRP must be an individual or corporate entity physically established in the United Kingdom (England, Wales, Scotland, or Northern Ireland) who holds an express, written mandate from the manufacturer. Crucially, an overseas manufacturer cannot appoint multiple UKRPs for different product lines or different regional territories within Great Britain: you must appoint a single UK Responsible Person for all devices placed on the market by that legal manufacturer ¹.

A frequent operational question from distributors is whether a commercial distributor can also serve as the manufacturer's UKRP. The answer under MHRA guidance is unambiguously yes: 'There is nothing to prevent an importer or distributor from also acting as a UK responsible person' ¹. However, combining these roles introduces commercial and regulatory trade-offs that must be addressed in distribution agreements:

• Commercial Exclusivity vs Portability: If your exclusive GB distributor is appointed as your UKRP, all DORS registrations reside within that distributor's MHRA portal account. If the commercial relationship terminates, transferring DORS registrations to a new UKRP requires formal account handovers, written mandate revocations, and administrative updates that can stall shipments if contested.
• Confidentiality of Technical Files: The UKRP must have immediate access to the full technical documentation, design history files, biocompatibility evaluation reports, and clinical evaluations to produce them upon MHRA demand. Manufacturers reluctant to share proprietary manufacturing files with a commercial partner often prefer appointing a neutral, professional third-party UKRP consultancy.
• Private-Label and Own-Brand Trap: If a British distributor buys sterile consumables from an OEM and places its own company name and logo on the packaging without identifying the original manufacturer, the distributor ceases to be a distributor and legally becomes the Virtual Manufacturer under UK MDR 2002. In this scenario, the British firm cannot simply reference the OEM's registration—it must hold the complete design and technical file and register the device under its own name. For detailed guidance on private-label liabilities and contract manufacturing audits, see our comprehensive guide on medical device contract manufacturing and private-label qualification.

What Must Be in MHRA DORS Before First Supply, What Does PARD Prove, and What Did the 1 April 2026 Fee Change Cost?

Under the UK MDR 2002 as amended, all medical devices, in vitro diagnostics, custom-made devices, and procedure packs must be formally registered with the MHRA before they are placed on the market in Great Britain ³. Device registration is performed electronically via the MHRA's Device Online Registration System (DORS) by the manufacturer (if UK-based) or by the designated UK Responsible Person (for overseas manufacturers).

Before structuring a product submission, distributors and manufacturers must understand what information DORS captures and what registration legally represents ³:

Registration of your devices with the MHRA (the UK Competent Authority) does not represent any form of accreditation, certification, approval or endorsement by the MHRA. Therefore, you are not permitted to make any claims to this effect, including the use of any MHRA logos in marketing materials, on device packaging, in the instructions for use, or in any other documentation.— MHRA, Register medical devices to place on the market (verified 23 August 2026)

The public output of DORS is the Public Access Registration Database (PARD) ¹². Hospital procurement officers and commercial partners routinely search PARD to confirm that a supplier's product is registered. However, seeing a product on PARD proves only that the administrative notification was completed; it does not prove clinical safety, manufacturing quality, or regulatory clearance. Once registered, a device can also serve as the prerequisite for obtaining a UK export certificate; for guidance on checking export documentation, see our analysis of verifying UK MHRA Certificates of Free Sale and export documentation.

The 1 April 2026 DORS Fee Reform: From One-Off Charge to £300 Annual GMDN Category Levies

Prior to 1 April 2026, registering a medical device on DORS was a one-time administrative transaction. An organisation paid a single statutory fee (historically £100–£240) per application, regardless of how many devices or GMDN categories were included in the registration.

On 1 April 2026, the MHRA enacted a major structural overhaul of its registration financing ³. The one-off registration fee was abolished and replaced with an annual charging scheme designed to fund ongoing national market surveillance and post-market enforcement. For the 2026/27 charging year (1 April 2026 to 31 March 2027), the statutory framework establishes the following fee rules:

• Unit Fee: £300 per year, per Level 2 GMDN® Category (or Level 1 Category where no Level 2 exists) registered within the manufacturer's DORS account.
• Portfolio Calculation: Fees are calculated based on the distinct Level 2 GMDN categories active on 31 March preceding the charging year. New registrations added mid-year are pro-rated accordingly.
• Payment Deadlines: The initial 2026 annual fee payment deadline was formally extended by the MHRA from June to 31 July 2026 ³.
• Account Sanctions: Failure to pay annual GMDN category fees results in suspension of the DORS registration, rendering subsequent market placements unlawful.
• Closure of Legacy Accounts: MHRA officially closed all legacy DORS accounts belonging to former Great Britain-based Authorised Representatives who failed to formally transition their roles to registered UK Responsible Persons by 30 March 2026 ³.

How Do Labelling Rules Differ for CE-Only Devices Versus UKCA or Dual-Marked Devices?

Product packaging, labelling, and Instructions for Use (IFU) represent the most visible operational divergence between CE-recognised and UKCA-marked devices. Over-specifying label requirements—such as forcing an overseas supplier to re-print outer cartons to add UKRP details to CE-only inventory—creates unnecessary friction, cost, and lead-time delays ¹.

The MHRA has established clear, distinct labelling rules governing what must appear on the physical product, primary sterile barrier, outer sales packaging, and accompanying documentation depending on the conformity mark affixed:

A critical operational takeaway for distributors is that a device relying exclusively on the CE-recognition route does NOT need to display the UK Responsible Person's name or address on its packaging or IFU ¹. The UKRP mandate is registered on MHRA DORS, and the CE label requires only the Legal Manufacturer and the EU Authorised Representative (EC REP). However, the moment a manufacturer affixes the UKCA mark—including on dual-marked packaging displaying both CE and UKCA logos—the UKRP's name and UK address become legally mandatory on the product label, outer packaging, or IFU ¹.

What Already Applies Even If You Never Affix UKCA: The 16 June 2025 Post-Market Surveillance Rules

The most significant regulatory shift in British medical device law since Brexit occurred on 16 June 2025, when The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024 No. 1368) entered into force ⁷¹¹. This legislation inserted a new Part 4A (regulations 44ZC to 44ZR, with scope at regulation 44ZD) into the UK MDR 2002, replacing the historical MEDDEV vigilance guidelines with a statutory post-market surveillance framework.

The crucial fact that many international manufacturers overlook is that SI 2024 No. 1368 applies to all medical devices placed on the market or put into service in Great Britain from 16 June 2025 onwards, regardless of certification ⁷. Even if your device relies 100% on a European CE mark and never touches a UK Approved Body, every single carton placed on the GB market after 16 June 2025 is subject to Great Britain's Part 4A PMS statutory obligations ⁸.

Regulation 44ZD applies Part 4A to devices placed on the market or put into service in Great Britain on or after 16 June 2025. Earlier placements sit outside Part 4A and remain on the pre-June 2025 UK vigilance arrangements ⁷¹¹. For current and future shipments, distribution agreements should lock in the 15-day, 10-day and 2-day incident clocks and the 3-working-day document production rule ⁸.

Northern Ireland Is Not Great Britain: CE Marking, EUDAMED from 28 May 2026, and Authorised Representatives

A frequent compliance error in UK market-access planning is treating the United Kingdom as a single, homogenous regulatory territory. Under the Northern Ireland Protocol and the Windsor Framework, Northern Ireland (NI) remains aligned with the European Union Single Market for goods, including medical devices ¹.

The rules governing Northern Ireland differ fundamentally from Great Britain across conformity marks, economic operator mandates, and registration databases:

A major administrative milestone occurred on 28 May 2026: the MHRA updated its statutory registration requirements to confirm that all medical devices (other than custom-made devices) placed on the Northern Ireland market must be registered in EUDAMED prior to market placement ³. From 28 May 2026 onwards, dual registration on MHRA DORS is no longer required for standard CE-marked devices entering Northern Ireland, eliminating double-registration burdens for European-bound supply chains ³.

What the Closed MHRA Consultation Proposed — and Why It Is Not Yet Law

Between 16 February 2026 and 10 April 2026, the MHRA conducted a high-profile, targeted public consultation entitled 'Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices' ⁴. This consultation proposed significant long-term policy shifts that have generated widespread speculation across medical device consultancies and trade media:

1. Indefinite CE Recognition for MDR/IVDR: Removing the 30 June 2030 cut-off date entirely, allowing devices compliant with EU MDR and EU IVDR to be placed on the Great Britain market indefinitely.
2. Extension of Legacy MDD Transitions: Further aligning the 30 June 2028 MDD transitional dates with the EU's extended transition periods under Regulation (EU) 2023/607 (up to December 2027 or December 2028 based on risk class).
3. International Reliance Framework: Establishing expedited reliance routes for medical devices authorised by comparable international regulators (such as the US FDA, Health Canada, and Australia TGA), particularly where a device is classified in a higher risk category in GB than in the EU ⁴⁶.

However, regulatory professionals and procurement executives must exercise extreme discipline: as of 23 August 2026, this consultation remains officially in the 'We are analysing your feedback' stage ⁴. The UK Government has not published its formal consultation response, nor has it laid a draft Statutory Instrument before Parliament to amend the 2028/2030 dates.

Furthermore, regulatory teams should note an internal inconsistency across official portals: while the live MHRA consultation page ⁴ accurately records that the consultation closed on 10 April 2026, the CE-timelines page ⁵ and the 'Implementation of the future regulations' overview ⁶ still contain stale text stating that the consultation is open. Distributors must rely on the live consultation tracking page and enacted legislation rather than static summary overviews. Until new primary regulations are made, the binding legal deadlines for Great Britain remain 30 June 2028 (MDD) and 30 June 2030 (MDR) ¹⁰.

Worked Portfolio Examples: CE-Marked Circumcision Rings vs NMPA-Only Laser Fibers

To illustrate how Great Britain's market placement rules apply in practice to real-world medical consumables, consider two contrasting device lines from the VEMERIX surgical and vascular portfolio:

Case Study 1: The CE-Marked Auto-Circumcision Ring (Class II)

The VEMERIX Auto-Circumcision Ring (Disposable Circumcision Device) is an NMPA Class II registered urological consumable (Lu Mech Reg. 20172020238) that holds an active, valid European CE Certificate of Conformity. For an international distributor introducing this line into the UK healthcare market in 2026, the regulatory pathway operates as follows:

• Conformity Route: The device qualifies for the CE-Recognition Route under SI 2023/627. Because it holds valid CE certification, it can be lawfully placed on the market in England, Wales, and Scotland until the applicable statutory deadline (30 June 2028 for MDD extension or 30 June 2030 for MDR) without undergoing a separate UKCA audit ⁵.
• UKRP Mandate: VEMERIX executes a formal written UKRP mandate with an established UK representative, who holds the CE declaration, technical file, and biocompatibility documentation on file ¹.
• DORS Registration: The UKRP registers the device under the appropriate GMDN category for circumcision rings on MHRA DORS and pays the annual statutory GMDN fee (£300/year for 2026/27) ³.
• Packaging & Labelling: The device uses standard CE packaging displaying the manufacturer name and EU Authorised Representative (EC REP). No UKRP details or UKCA logos are required on the physical label or blister pack ¹.
• Post-Market Vigilance: All batches placed on the GB market after 16 June 2025 are monitored under Part 4A PMS rules, including the 15-day serious incident reporting window ⁷. For the wider clinical and evidence background on this platform, see our market-entry evidence pack for disposable circumcision devices.

Case Study 2: NMPA-Registered Single-Use Medical Laser Fiber (Class II)

In contrast, Medison's Disposable Medical Laser Fiber is an NMPA-registered Class II vascular consumable (Lu Mech Reg. 20192010517) engineered for 1470 nm endovenous laser ablation workflows. In the company's official product baseline, this consumable holds Chinese NMPA approval; ISO 13485 describes the manufacturer's quality system, not a product CE certificate. This SKU does not carry an EU CE mark.

• Conformity Route: The CE-recognition pathway is completely unavailable for this SKU in Great Britain because no underlying EU CE certificate exists. Chinese NMPA registration and an ISO 13485 certificate do not confer GB market access.
• Market Placement Requirement: To enter Great Britain, this product line must either complete a conformity assessment with a UK Approved Body to obtain a UKCA Mark under UK MDR 2002, or obtain an EU MDR CE certificate.
• Commercial Integrity: A distributor cannot place this fiber on the GB market using DORS registration alone; DORS requires entering a valid conformity certificate reference. For a complete analysis of the technical specifications and registration requirements for this vascular line, see the registration evidence pack for single-use endovenous laser fibers.

Distributor Checklist, Agreement Terms, and Red Flags Before the First GB Shipment

Before executing a distribution agreement, issuing a purchase order, or clearing customs for a medical device shipment entering Great Britain, distributors and procurement teams should audit the transaction against the following 10-point due diligence checklist:

1. Confirm Legal Pathway: Verify whether the SKU relies on CE Recognition (SI 2023/627) or UKCA Marking (UK MDR 2002). Never accept generic statements like 'compliant for export'.
2. Audit CE Certificate Validity: If relying on CE recognition, verify the Notified Body designation on NANDO, confirm the certificate covers the exact model/SKU, and check whether MDD validity is supported by EU 2023/607 extension documents.
3. Inspect UKRP Written Mandate: Confirm that the manufacturer has appointed a single, UK-established UK Responsible Person under a formal written mandate defining regulatory and vigilance duties.
4. Verify MHRA DORS Listing on PARD: Search the MHRA PARD portal to confirm the device model, brand name, GMDN code, and UKRP details are actively registered.
5. Confirm 2026/27 Annual Fee Payment: Ensure the UKRP has settled the 2026/27 annual GMDN category fees (£300/category) to prevent administrative suspension.
6. Audit GB Importer Notification: Confirm that your British importing legal entity has been formally notified to the MHRA by the UKRP.
7. Audit Physical Labelling & Packaging: For CE-only stock, ensure packaging carries legal manufacturer and EC REP (UKRP not required). For UKCA or dual-marked stock, verify UKRP name and address are present on label, outer pack, or IFU.
8. Implement June 2025 PMS Escalation: Ensure the distribution contract includes a binding clause requiring the distributor to report complaints and adverse events to the UKRP within 48 hours to meet the MHRA 15-day serious incident statutory deadline.
9. Check Northern Ireland Routing: If goods are destined for Northern Ireland, verify full EU MDR/IVDR compliance, EC REP details, and confirm EUDAMED registration (mandatory since 28 May 2026).
10. Separate QMS from Market Clearance: Confirm that an ISO 13485 certificate is treated as a quality baseline, not confused with MHRA device registration or conformity certification. For guidance on auditing QMS documentation, see our distributor guide to verifying supplier ISO 13485 certificates.

Seven Red Flags That Should Immediately Halt Great Britain Sourcing

• ❌ Claiming 'MHRA Approved' or 'MHRA Certified': The MHRA does not issue product approvals or certificates for standard medical devices. Any supplier using this phrase or displaying an MHRA logo is in direct violation of UK regulations.
• ❌ Multiple UKRPs for One Manufacturer: An overseas manufacturer attempting to appoint different UKRPs for different UK distributors. UK law permits only one single UKRP per legal manufacturer.
• ❌ Treating PARD Search as Product Clearance: Assuming that because a product name appears in PARD search results, the MHRA has vetted its clinical safety or performance.
• ❌ Unbacked MDD Extensions: Sourcing CE-marked goods under an expired MDD certificate without the formal EU 2023/607 confirmation letter and notified body written agreement.
• ❌ Pre-2025 Vigilance Timelines in Contracts: Distribution contracts referencing 30-day serious incident reporting instead of Great Britain's mandatory 15-day statutory window under SI 2024 No. 1368.
• ❌ Shipping UKCA-Only Stock to Northern Ireland: Attempting to supply Belfast hospitals with UKCA-marked goods that lack an EU CE mark.
• ❌ Treating the Closed CE Consultation as Law: Planning commercial supply chains on the assumption that indefinite CE recognition is already enacted.

Where VEMERIX Fits — And Where Due Diligence Still Begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care. Our manufacturing facilities operate under certified ISO 13485 quality management systems, and our product portfolio encompasses NMPA-registered sterile single-use surgical consumables, with CE marking only where a valid EU certificate is in force for that SKU.

When partnering with international distributors and OEM buyers targeting the Great Britain healthcare market, VEMERIX provides complete regulatory transparency and documentation support across every market-access gate:

• Validated CE Documentation: For our CE-marked product lines—including the Auto-Circumcision Ring—we provide verified Notified Body certificates, Declarations of Conformity, and technical documentation ready for UKRP review and DORS registration under SI 2023/627.
• Non-CE Sku Transparency: For product lines holding Chinese NMPA registration and ISO 13485 certification without European CE marks—such as our single-use medical laser fiber—we provide full engineering dossiers, biological evaluation reports (ISO 10993), and sterilization validations to support distributor-led UKCA conformity assessment or OEM private-label registration.
• UKRP Mandate & DORS Enablement: We coordinate directly with designated UK Responsible Persons to facilitate seamless DORS data submission, GMDN code alignment, and importer notification records.
• Part 4A PMS Compliance Integration: Our post-market surveillance systems, customer feedback channels, and vigilance escalation workflows are structured to support the 15-day, 10-day and 2-day incident reporting windows and the 3-working-day document production rule in SI 2024 No. 1368.

We invite medical device distributors, NHS framework suppliers, and private-label partners to review our clinical solutions at Clinical Solutions, inspect our quality and regulatory certifications at Quality & Regulatory, download technical catalogues at Downloads, or contact our international regulatory team at Contact VEMERIX to request a complete GB regulatory pack for your target product lines.

Frequently Asked Questions

Do I need a UKCA mark to sell a CE-marked sterile medical device in England in 2026?

No. Under The Medical Devices (Amendment) (Great Britain) Regulations 2023 (SI 2023 No. 627), Great Britain continues to recognise valid EU CE marks. Devices with valid MDD/AIMDD certificates may be placed on the market until the sooner of certificate expiry or 30 June 2028; IVDD certificates until the sooner of expiry or 30 June 2030; and devices compliant with EU MDR 2017/745 or IVDR 2017/746 until 30 June 2030. You do not need a UKCA mark if your CE certificate remains valid under those recognition rules, provided you appoint a UK Responsible Person, register the device on MHRA DORS, and comply with UK PMS regulations.

Is MHRA DORS registration the same as MHRA approval?

No. Registration on MHRA DORS is an administrative notification of market placement, not an approval, certification, or safety endorsement. The MHRA explicitly prohibits manufacturers and distributors from claiming their products are 'MHRA Approved' or using MHRA logos on marketing materials and packaging.

Can my Great Britain distributor also act as my UK Responsible Person (UKRP)?

Yes. UK regulations permit a UK-established distributor or importer to also act as the designated UK Responsible Person, provided there is an express written mandate. However, because all DORS registrations reside in the UKRP's account, manufacturers must consider commercial flexibility if the distribution contract terminates, or alternatively appoint an independent third-party UKRP.

Does a CE-only marked device have to show the UKRP name and address on the packaging or label?

No. For devices placed on the Great Britain market relying exclusively on the CE-recognition route, UKRP details do NOT need to appear on the product label, outer packaging, or IFU (they are recorded in MHRA DORS). UKRP details are mandatory on packaging or IFU only when the UKCA mark (or dual CE + UKCA marking) is affixed.

If my EU MDD certificate has expired, can I still place the device on the Great Britain market?

Only if the certificate is legally considered valid under European Union Regulation (EU) 2023/607 transition extensions. If the manufacturer met the formal extension conditions (lodging an MDR application, signed notified body agreement, no unacceptable risk), the certificate is accepted in GB until 30 June 2028. If the certificate expired without satisfying EU extension rules, the device cannot be placed on the GB market under CE recognition.

Do the June 2025 PMS rules apply to CE-marked devices, or only to UKCA-marked devices?

They apply to both. The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024 No. 1368) applies to all medical devices placed on the Great Britain market from 16 June 2025 onwards, regardless of CE or UKCA marking. That includes 15-day serious-incident reporting, 10-day reporting for death or unanticipated serious deterioration, 2-day reporting for a serious public-health threat, and production of the PMS plan, PMSR or PSUR within 3 working days of an MHRA request.

Can I use the UKCA mark to sell medical devices in Northern Ireland or the European Union?

No. The UKCA mark is recognised exclusively in Great Britain (England, Wales, Scotland). It is NOT recognised in the European Union or Northern Ireland. Northern Ireland requires CE marking under EU MDR/IVDR, and devices placed in NI must be registered on EUDAMED since 28 May 2026.

Has the MHRA already decided to recognise CE marks indefinitely?

No. While the MHRA held a targeted consultation between February and April 2026 proposing indefinite CE recognition for EU MDR/IVDR devices, as of 23 August 2026 that consultation is closed and remains in the 'analysing feedback' stage. No legislation has been enacted, so the statutory deadlines of 30 June 2028 (MDD) and 30 June 2030 (MDR) remain the binding law in Great Britain.